Understanding the Mechanism of Radionuclides and Survival in Bone Mets in CRPC
The Challenge of Bone-Metastatic PC
PC: Unique Pattern of Metastasis
Biology of Bone Mets in PC
Tumor Cells Compete With Stem Cells in PC
"Vicious Cycle" of PC Bone Mets
Bone Mets in PC: Predisposing Factors
Consequences of Bony Metastatic Disease
FDA-Approved Bone-Targeted Treatments
"The Land of No Indication"
Approved Uses of Bone-Targeted Therapies
Dosing Zoledronic Acid and Denosumab in PC
Do Zoledronic Acid and Denosumab Add Value in the Modern Treatment Era?
Docetaxel ZA: SRE-Free Interval
Enzalutamide Post-Docetaxel: Time to SRE
Enzalutamide Increases Fracture Rates
Abiraterone Prednisone Postdocetaxel: Fractures (COU-AA-301)
Advanced PC: Heterogeneous Group of Diseases
Preferential Uptake of Radium-223 in Osteoblastic Lesions
ALSYMPCA Trial of Radium-223: Survival
ALSYMPCA Trial of Radium-223: Time to SSEs
ALSYMPCA Trial: Effects of Radium-223 on SSEs, Stratified by Bisphosphonate Use
Lessons From ALSYMPCA
Can Radium Add Value to Abiraterone or Enzalutamide in Bone-Metastatic CRPC?
If Concomitant Hormonal Therapy Is Used, When Should Radium-223 Be Added?
Potential to Target PSMA
PSA Decline With PSMA-Targeted Therapy
Case Report: PSMA-Targeted Alpha Emitter (Actinium-225)
The Future of Targeted Radiation in PC
Summary
Abbreviations